ALK Expanded Tablet Manufacturing Partnership
The company has committed DKK 500 million to increase its production capacity for allergy treatments.
Updated on Sept. 30, 2026 in Allergies
Live Poll
Do you believe long-term pharmaceutical manufacturing partnerships increase drug availability for patients?
ALK has extended its long-term manufacturing partnership with Catalent to secure future supply for its allergen tablet portfolio. The agreement includes a DKK 500 million investment to expand production sites in the UK and Canada.
Why it matters
The investment aims to ensure supply robustness for allergy products by meeting projected future demand for the company's sublingual immunotherapy tablets.
ALK will invest DKK 500 million over three years to achieve an annual production capacity of 1.1 billion tablets by the early 2030s. This represents a 300 million unit increase from prior capacity levels.
The players
ALK
This Denmark-based company is a global leader in allergy immunotherapy products.
Catalent
This company provides advanced delivery technologies and manufacturing solutions for the pharmaceutical industry.
The details
The contract grants ALK long-term access to specialized Zydis tablet technology, building on a collaboration between the two companies that has spanned over two decades. The capital expenditures will be recorded on the company's balance sheet and do not impact current 2026 financial guidance.
Timeline
September 30, 2026: ALK announced the expanded partnership agreement.
Over the next three years: ALK will pay DKK 500 million for capacity expansion.
Early 2030s: The firm expects to begin operating at a capacity of 1.1 billion tablets.
The Big Picture
The agreement centers on securing long-term access to the Zydis tablet technology platform. By locking in this specific delivery method, the firm ensures its production capabilities remain aligned with specialized drug formulation standards.
This investment is intended to ensure consistent supply of allergy treatments, which may reduce the risk of future product shortages for patients relying on these therapies. The manufacturing upgrades are not expected to impact the current cost or accessibility of treatments for consumers.
The takeaway
Securing robust manufacturing capacity is a critical step for companies managing complex pharmaceutical supply chains for chronic health conditions. Ensuring long-term production stability helps companies like ALK meet rising demand without immediate disruption to current financial performance.
Further reading
For more information on the evolving landscape of immunotherapy, visit the Allergies section.
Live Poll
Do you believe long-term pharmaceutical manufacturing partnerships increase drug availability for patients?
